A study published in the New England Journal of Medicine (2007) identifies JAK2 exon 12 mutations as a distinct cause of myeloproliferative disorders, including polycythemia vera and idiopathic erythrocytosis. The research team, including researchers from the University of Cambridge, Whitehead Institute, and other institutions, analyzed 10 patients without the V617F mutation in the JAK2 gene. They found four somatic gain-of-function mutations in JAK2 exon 12, which led to isolated erythrocytosis and distinctive bone marrow morphology. These mutations resulted in erythroid colonies that could grow without exogenous erythropoietin and were heterozygous for the mutation. In contrast, patients with the V617F mutation were typically homozygous. The mutations also caused increased phosphorylation of JAK2 and extracellular regulated kinase 1 and 2, and led to a myeloproliferative phenotype in a murine model. The study highlights that JAK2 exon 12 mutations define a distinct myeloproliferative syndrome, affecting patients diagnosed with polycythemia vera or idiopathic erythrocytosis. The findings suggest that these mutations are a significant cause of these disorders, and emphasize the importance of molecular classification for accurate diagnosis and treatment. The study also discusses the clinical features and implications of these mutations, including lower serum erythropoietin levels, distinct bone marrow morphology, and the presence of erythroid colonies. The research provides insights into the molecular basis of these disorders and the role of JAK2 mutations in their development.A study published in the New England Journal of Medicine (2007) identifies JAK2 exon 12 mutations as a distinct cause of myeloproliferative disorders, including polycythemia vera and idiopathic erythrocytosis. The research team, including researchers from the University of Cambridge, Whitehead Institute, and other institutions, analyzed 10 patients without the V617F mutation in the JAK2 gene. They found four somatic gain-of-function mutations in JAK2 exon 12, which led to isolated erythrocytosis and distinctive bone marrow morphology. These mutations resulted in erythroid colonies that could grow without exogenous erythropoietin and were heterozygous for the mutation. In contrast, patients with the V617F mutation were typically homozygous. The mutations also caused increased phosphorylation of JAK2 and extracellular regulated kinase 1 and 2, and led to a myeloproliferative phenotype in a murine model. The study highlights that JAK2 exon 12 mutations define a distinct myeloproliferative syndrome, affecting patients diagnosed with polycythemia vera or idiopathic erythrocytosis. The findings suggest that these mutations are a significant cause of these disorders, and emphasize the importance of molecular classification for accurate diagnosis and treatment. The study also discusses the clinical features and implications of these mutations, including lower serum erythropoietin levels, distinct bone marrow morphology, and the presence of erythroid colonies. The research provides insights into the molecular basis of these disorders and the role of JAK2 mutations in their development.